Clinical Efficacy and Safety Evaluation of Teneligliptin in Type 2 Diabetes Who Have Inadequate GlycemIc Control With Empaglyflozin and Metformin

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 235 participants.

Also called NCT05504239

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 235 participants (enrolled count) (from the registry)
Sponsor
  • Handok Inc. Registry lists this organization as the lead sponsor
Registry
  • NCT NCT05504239
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
South Korea (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT05504239. Randomized; quadruple masking; primary purpose treatment. Start 2022-09-27 (actual); primary completion 2024-04-23 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Clinical Efficacy and Safety Evaluation of Teneligliptin in Type 2 Diabetes Who Have Inadequate GlycemIc Control With Empaglyflozin and Metformin
Acronym
TERA 304
Intervention (Drug)
Teneligliptin (as Teneligliptin Hydrobromide) 20 Mg Oral Tablet
Intervention (Drug)
Teneligliptin Placebo Oral Tablet
Lead sponsor
Handok Inc. (class: industry)

Record details

Record id
cardio:ct-nct05504239
Content hash
e4acd41eecccbdd097ab94a1d1480774c55b879cfa2ac45135a58d26d8aa9219